Johnson & Johnson just listed out the drugs it plans to file for approval over the next few years that could be “blockbusters.”
These are drugs that haven’t been approved yet, but by 2021, they could be making more than $US1 billion in annual sales each.
Right now, the world’s largest drugmaker is known for its immunology drugs like Remicade, which made $US4.8 billion in sales in 2016 and Stelara, as well as the bloodthinner Xarelto, which made $US2.2 billion in sales in 2016.
Here’s the list of drugs J&J plans to file for approval over the next four years that could hit that blockbuster threshold, including cancer and depression treatments:
- guselkumab – psoriasis (Filed for approval in 2016)
- sirukumab – rheumatoid arthritis (Filed for approval in 2016)
- apalutamide – pre-metastatic prostate cancer
- esketamine – treatment-resistant depression
- talacotuzumab – acute myeloid leukemia, a type of blood cancer
- erdafitinib – solid tumours
- niraparib – prostate cancer
- imetelstat – myelofibrosis, a bone marrow disorder
- pimodivir – influenza A
- lumicitabine – respiratory syncytial virus (RSV) infection
- JNJ-7922 – adjunctive treatment for major depressive disorder
More from Lydia Ramsey:
- The prices for life-saving diabetes medications have increased again
- A promising new cancer treatment is facing a deadly setback
- Insiders reveal how Boston moved to the forefront of the global fight against deadly diseases
- There could a better way to protect against the flu, and it has implications for tackling HIV and the common cold (SNY)
- A startup that wants to build an early-warning system for cancer just raised $US360 million
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.